Chinese artificial intelligence company XtalPi has agreed terms for a $250 million collaboration with Eli Lilly (NYSE: LLY).
The AI drug discovery project will leverage XtalPi's integrated AI capabilities and robotics platform, ID4Inno, to design and deliver drug candidates.
The company is working on so-called "dry lab" algorithms together with large-scale "wet lab" robotics, and has developed a proprietary set of techniques that Lilly hopes to leverage against an undisclosed target.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze